Clinical trials: Primary Cancer of the Peritoneum
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005026
- Testing
- carboplatin, paclitaxel, topotecan hydrochloride
- Where
- 47 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Peritoneal Primary Cancer
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
RATIONALE: Chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ovarian Cancer, Peritoneal Primary Cancer, Fallopian Tube Cancer
- Trial name
- NCT00293293
- Testing
- healing touch, massage therapy, hypnosis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020696
- Testing
- cisplatin, tirapazamine
- Where
- 54 sites in United States, Australia and 2 more
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087087
- Testing
- pemetrexed disodium
- Where
- 35 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Tumor of Female Reproductive System, Ovarian Cancer
A Cohort Establishment Study of Total Management of Ovarian Cancer
A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).
- Trial name
- NCT06018935
- Testing
- No intervention
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Primary Peritoneal Carcinoma, Stage III Ovarian Cancer
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is most effective in treating ovarian epithelial cancer and…
- Conditions
- Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT00011986
- Testing
- Paclitaxel, Carboplatin, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 4,312 people
- Sponsor
- Gynecologic Oncology Group
Fallopian Tube Cancer, Ovarian Cancer
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to determine the effectiveness of imatinib mesylate in treating patients who have…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00039585
- Testing
- imatinib mesylate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may slow the growth of ovarian epithelial cancer or primary peritoneal cancer.
- Trial name
- NCT00023699
- Testing
- gefitinib
- Where
- 53 sites in United States, Australia and 2 more
- Sponsor
- Gynecologic Oncology Group
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer that has not responded to previous treatment.
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00036751
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)